Drug Profile
Research programme: epigenetic targeted therapeutics - Aurigene Oncology/Orion
Alternative Names: Menin-MLL targeted molecule - Aurigene Oncology/Orion; PRMT5 targeted molecule - Aurigene Oncology/OrionLatest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Menin modulators; PRMT5 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Cancer in India (unspecified route)(aurigene discovery technologies pipeline, February 2023)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Cancer in India
- 01 Sep 2017 Preclinical development is ongoing in India (Aurigene pipeline, September 2017)